still bad start
improv pt
put beat tweak full-year guid impli step-down
growth primarili fx near-term optic asid stori overal continu
improv stack rate breast molecular still acceler ou gain
momentum declin aesthet moder first time year
back basic playbook quietli work tweak higher
rais pt prior
breast us jump could leg follow fda polici updat us breast
imag improv last combin healthi capit
environ increas purchas order follow fda propos improv
mqsa regul mammographi facil releas late march although
propos final comment period end late june new standard
clear requir facil uniform screen capabl dens breast
patient saw earli gain stand disproportion benefit given
geniu system still offer dens breast claim attach
look ahead final new mqsa rule could prove boon co consid
upgrad opportun base gantri still left us last
increment share gain competitor still lack densiti claim
diagnost keep place panther keep throw overal
diagnost ex-blood screen grew steadi sequenti cc support still
acceler growth molecular advanc stack basi tough
comp consid cc vs last year perform come
face sever new competit launch abbott alin siemen atellica roch
coba advanc renew contract quest lab corp presum lower
price despit headwind continu see gain continu volum
share gain on/with panther mid-siz lab volum side test menu
continu pay steadi dividend overal valu prop panther still drive
aesthet still drag cyno declin moder first time year aesthet
ahead expect actual us declin improv
third consecut ou turn posit first time year
divis women still declin follow fda warn letter last year
declin bodi contour moder part driven sculpsur skin
post posit growth although overal declin expect continu near-term
co increasingli confid path modest growth still lie ahead
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
mqsa mammographi standard around breast
diagnost grow msd-to-hsd driven molecular
panther test menu continu expand next
thinprep novasur experi flat modest
growth next month
aesthet declin moder
tuck-in deal add growth
base pt use revis ep
breast growth improv hsd follow fda
polici chang mqsa mammographi standard
panther instal exceed surpass
test revenu per system menu expans
thinprep novasur experi mid-singl digit
growth next month
aesthet return lsd sooner expect
cyno sold tuck-in add immedi
chang mqsa mammographi standard
diagnost slow lsd panther share
aesthet return mid-teen declin cyno
thinprep novasur experi lsd declin
next month
compani unabl execut oper effici
buy predic return focu breast
molecular make revenu
grow well cynosur becom less focu
drag part busi remain stabl
top-line growth mid-sd includ acquisit
ep growth high-sd
final rule fda polici recommend mqsa
panther menu clearanc launch
cyno product launch updat
pleas see import disclosur inform page report
rais pt buy
settl steadi msd growth mode
rais prior reflect faster growth
breast revis prior well molecular revis prior
coupl slower declin aesthet revis prior rais
pt prior reflect continu improv core breast molecular
busi tailwind suffici enough sustain growth well
next year seemingli continu coupl tuck-in capabl drive
steadi growth accret establish vertic
pleas see import disclosur inform page report
pleas see import disclosur inform page report
eseptdecmarjunseptseptdecmarjunseptseptseptsepttot ex-fx product servic oper interest expens loss tax incom adj ep share exhibit revenu model
pleas see import disclosur inform page report
inc develop manufactur distribut medic imag system diagnost surgic product women
oper four segment breast diagnost gyn surgic skelet breast segment offer
breast imag product selenia full field digit mammographi system breast tomosynthesi approv europ
mammosit radiat therapi system mammopad breast cushion photoconductor coat segment also develop
breast imag platform dimens util tomosynthesi technolog produc imag ce mark fda approv
pend diagnost segment provid thinprep system primarili use cytolog test applic cervic
cancer screen rapid fetal fibronectin test pre-term birth risk assess human papillomaviru offer invitro
diagnost cervic cancer test gyn surgic segment offer novasur system minimally-invas procedur allow
physician treat women suffer excess menstrual bleed adiana system form perman femal contracept
intend altern tubal ligat skelet health segment provid qdr x-ray bone densitomet assess bone
densiti fractur site sahara clinic bone sonomet assess bone densiti heel c-arm imag system
use perform minim invas surgic procedur patient extrem extrem mri detect rheumatoid arthriti
orthoped found headquart bedford massachusett
pt ep forecast slight discount peer risk cyno integr slow cycl guidelin shift
raj denhoy certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
anthoni petron cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
